Literature DB >> 21880298

Transcatheter aortic valve implantation or surgical aortic valve replacement as redo procedure after prior coronary artery bypass grafting.

Stefan Stortecky1, Henriette Brinks, Peter Wenaweser, Christoph Huber, Thomas Pilgrim, Stephan Windecker, Thierry Carrel, Alexander Kadner.   

Abstract

BACKGROUND: The perioperative risk for redo surgical aortic valve replacement (S-AVR) in patients with severe aortic stenosis and prior coronary artery bypass grafting (CABG) is increased. Transcatheter aortic valve implantation (TAVI) represents an alternative. We assessed the perioperative and mid-term clinical outcome of patients undergoing S-AVR or TAVI.
METHODS: In a retrospective observational, comparative study, 40 consecutive patients underwent redo operation with S-AVR or TAVI between April 2005 and April 2010. Median sternotomy and extracorporeal circulation were used for S-AVR; TAVI access was transfemoral (n = 27; 67.5%), transapical (n = 11; 27.5%), or transsubclavian (n = 2; 5.0%). Clinical and echocardiographic follow-up was at 30 days and 6 months.
RESULTS: TAVI patients were older (78.5 ± 6 vs 70.6 ± 8 years, p < 0.001) and presented higher logistic (33.5 ± 17 vs 20.2 ± 14, p < 0.001) European System for Cardiac Operative Risk Evaluation scores. All-cause mortality was 2.5% in both groups and major adverse cardiac and cerebrovascular event rates were comparable (7.5% TAVI vs 17.5% S-AVR, p = 0.311) after 30 days. TAVI was associated with a higher rate of permanent pacemaker implantation (30% vs 0%, p < 0.001) and grade II residual aortic regurgitation in 14%. Incidence of cerebrovascular events was 7.5% in S-AVR vs 2.5% in TAVI (p = 0.61).
CONCLUSIONS: In elderly, high-risk patients after prior CABG, conventional aortic valve replacement and TAVI are comparable treatment options with favorable clinical outcome. A redo operation itself does not sufficiently justify a TAVI approach.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21880298     DOI: 10.1016/j.athoracsur.2011.05.106

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  12 in total

1.  Results of surgical aortic valve replacement and transapical transcatheter aortic valve replacement in patients with previous coronary artery bypass grafting.

Authors:  Francesco Onorati; Augusto D'Onofrio; Fausto Biancari; Stefano Salizzoni; Marisa De Feo; Marco Agrifoglio; Giovanni Mariscalco; Vincenzo Lucchetti; Antonio Messina; Francesco Musumeci; Giuseppe Santarpino; Giampiero Esposito; Francesco Santini; Paolo Magagna; Cesare Beghi; Marco Aiello; Ester Dalla Ratta; Carlo Savini; Giovanni Troise; Mauro Cassese; Theodor Fischlein; Mattia Glauber; Giancarlo Passerone; Giuseppe Punta; Tatu Juvonen; Ottavio Alfieri; Davide Gabbieri; Domenico Mangino; Andrea Agostinelli; Ugolino Livi; Omar Di Gregorio; Alessandro Minati; Mauro Rinaldi; Gino Gerosa; Giuseppe Faggian
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-03-14

Review 2.  Role of transcatheter aortic valve implantation (TAVI) versus conventional aortic valve replacement in the treatment of aortic valve disease.

Authors:  Gerald M Lawrie
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Apr-Jun

3.  Systematic review and meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis.

Authors:  Christopher Cao; Su C Ang; Praveen Indraratna; Con Manganas; Paul Bannon; Deborah Black; David Tian; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2013-01

4.  Transcatheter versus surgical aortic valve replacement: a systematic review and meta-analysis of randomised and non-randomised trials.

Authors:  Vinayak Nagaraja; Jwalant Raval; Guy D Eslick; Andrew T L Ong
Journal:  Open Heart       Date:  2014-08-12

5.  Transapical transcatheter aortic valve replacement in patients with or without prior coronary artery bypass graft operation.

Authors:  Konstantinos V Voudris; S Chiu Wong; Ryan Kaple; Polydoros N Kampaktsis; Andreas R de Biasi; Jonathan S Weiss; Richard Devereux; Karl Krieger; Luke Kim; Rajesh V Swaminathan; Dmitriy N Feldman; Harsimran Singh; Nikolaos J Skubas; Robert M Minutello; Geoffrey Bergman; Arash Salemi
Journal:  J Cardiothorac Surg       Date:  2016-11-29       Impact factor: 1.637

Review 6.  Transcatheter versus Surgical Aortic Valve Replacement after Previous Cardiac Surgery: A Systematic Review and Meta-Analysis.

Authors:  Sharaf-Eldin Shehada; Yacine Elhmidi; Öznur Öztürk; Markus Kasel; Antonio H Frangieh; Fanar Mourad; Jaroslav Benedik; Jaafar El Bahi; Mohamed El Gabry; Matthias Thielmann; Heinz Jakob; Daniel Wendt
Journal:  Cardiol Res Pract       Date:  2018-04-05       Impact factor: 1.866

Review 7.  Functional status and quality of life after transcatheter aortic valve replacement: a systematic review.

Authors:  Caroline A Kim; Suraj P Rasania; Jonathan Afilalo; Jeffrey J Popma; Lewis A Lipsitz; Dae Hyun Kim
Journal:  Ann Intern Med       Date:  2014-02-18       Impact factor: 25.391

8.  Propensity matched analysis of longterm outcomes following transcatheter based aortic valve implantation versus classic aortic valve replacement in patients with previous cardiac surgery.

Authors:  Nestoras Papadopoulos; Nina Schiller; Stephan Fichtlscherer; Ralf Lehmann; Christian F Weber; Anton Moritz; Mirko Doss; Andreas Zierer
Journal:  J Cardiothorac Surg       Date:  2014-06-10       Impact factor: 1.637

Review 9.  Transcatheter Aortic Valve Replacement: a Kidney's Perspective.

Authors:  Wisit Cheungpasitporn; Charat Thongprayoon; Kianoush Kashani
Journal:  J Renal Inj Prev       Date:  2016-01-18

10.  Impact of coronary artery disease on outcomes of severe aortic stenosis treatment with transcatheter aortic valve implantation.

Authors:  Piotr Chodór; Krzysztof Wilczek; Łukasz Włoch; Roman Przybylski; Jan Głowacki; Tomasz Kukulski; Tomasz Niklewski; Marian Zembala; Mariusz Gąsior; Zbigniew Kalarus
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-04-09       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.